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Background: Alterations in surfactant phospholipid compositions are a recognized feature of many acute and
chronic lung diseases. Investigation of underlying mechanisms requires assessment of surfactant phospholipid
molecular composition and kinetics of synthesis and turnover. Such studies have recently become possible in
humans due to the development of stable isotope labelling combined with advances in analytical methods in
lipidomics. The objectives of this study are to compare phospholipid molecular species composition and
phosphatidylcholine synthesis and turnover in surfactant isolated from various endobronchial compartments in
healthy adults.
Methods: Healthy adults (N = 10) were infused with methyl-D9-choline chloride and samples of induced sputum,
tracheal wash and small volume bronchoalveolar lavage fluid were obtained subsequently at intervals up to 96 hours.
Surfactant phospholipid composition and incorporation of stable isotope into surfactant phosphatidylcholine were
determined by electrospray ionisation mass spectrometry.
Results: While molecular species compositions of phospholipids were similar for all three sample types,
dipalmitoylphosphatidylcholine content was highest in lavage, intermediate in tracheal wash and lowest in sputum.
Methyl-D9-choline incorporation into surfactant phosphatidylcholine was lower for sputum at 24 hours but reached
equilibrium with other sample types by 48 hours. Fractional methyl-D9-dipalmitoylphosphatidylcholine incorporation for
all sample types was about 0.5% of the endogenous composition. Lysophosphatidylcholine enrichment was twice than
that of phosphatidylcholine.
Conclusions: Tracheal secretions may be of value as a surrogate to assess bronchoalveolar lavage fluid surfactant
molecular composition and metabolism in healthy people. Despite minor differences, the phospholipid molecular
composition of induced sputum also showed similarities to that of bronchoalveolar lavage fluid. Detailed analysis of
newly synthesized individual phosphatidylcholine species provided novel insights into mechanisms of surfactant
synthesis and acyl remodelling. Lysophosphatidylcholine methyl-D9 incorporation patterns suggest that these species
are secreted together with other surfactant phospholipids and are not generated in the air spaces by hydrolysis of
secreted surfactant phosphatidylcholine. Application into patient populations may elucidate potential underlying
pathophysiological mechanisms that lead to surfactant alterations in disease states.
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Continued synthesis and secretion of pulmonary surfac-
tant is critically important for maintenance of optimal
lung function throughout life. While primary surfactant
deficiency in the lungs of preterm infants is widely
acknowledged as a major cause of neonatal respiratory
distress syndrome, secondary surfactant deficiency con-
tributes to the pathology of many respiratory disorders
of the mature lung including acute lung injury (ALI)/
acute respiratory distress syndrome (ARDS), asthma and
cystic fibrosis [1]. Described mechanisms for surfactant
dysfunction in respiratory diseases include inhibition
by plasma proteins such as fibrinogen in oedema fluid,
impaired synthesis and secretion by type II alveolar
epithelial (ATII) cells and hydrolysis or oxidation of
secreted surfactant [2]. Differentiating between these
potential mechanisms is problematical in the clinical
setting. Acquiring samples of alveolar and/or bronchial se-
cretions for analysis of surfactant function or composition
typically involves invasive bronchoscopic and bronchoal-
veolar lavage (BAL) procedures [3]. Additionally, analysis
of concentrations and compositions of surfactant com-
ponents such as surfactant proteins or phospholipids
provides no information about processes of surfactant syn-
thesis, secretion or turnover [4,5]. Availability of such in-
formation has considerable potential clinical implications,
both for better understanding mechanisms of lung disease
and for optimizing treatments for individual patients.
Consequently, in this study we have assessed the molecu-
lar specificity of surfactant phospholipids extracted from
small volume bronchoalveolar lavage fluid (BALF), tra-
cheal wash (TW) and induced sputum (IS), representing
secretions from various endobronchial compartments.
In addition, we employed an in vivo stable isotope label-
ling strategy to monitor the incorporation of methyl-
D9-choline chloride into the phosphatidylcholine (PC)
and lysophosphatidylcholine (LPC) fractions of the three
different sample types. PC, especially the disaturated dipal-
mitoyl species (PC16:0/16:0), is the major surface active
component of surfactant phospholipid. This stable isotope
methodology enables the assessment of both the rate of
synthesis and secretion of individual molecular species of
surfactant PC and the specificity of fatty acyl remodelling
mechanisms involved in their synthesis. This detailed ana-
lysis not only provides important information about me-
chanisms of surfactant PC synthesis and secretion, but
comparison of fractional incorporation rates between sam-
ple types can also demonstrate the time required for newly
secreted alveolar surfactant to transit to the upper airways.
Methods
Materials
Methyl-D9-choline chloride was from Cambridge Isotopes
(CK Gases, Ibstock, UK); dimyristoylphosphatidylcholine(PC14:0/14:0), heptadecyllysophosphatidylcholine (LP
C17:0) and dimyristoylphosphatidylglycerol (PG14:0/14:0)
were from Avanti Polar Lipids (Alabaster, USA). Solvents
of HPLC quality from Fisher Scientific, UK.
Study population
Ten healthy volunteers without pre-existing lung diseases
were recruited. All were non-smokers and had a normal
medical examination including spirometry. Subjects with
recent (within and up to 4 weeks) history of upper or
lower respiratory tract infections were excluded. The age
range was 18–36 with a median age of 26. The study pro-
tocol was approved by national ethics committee (South
Central, Berkshire 11/SC/0185) and the University Hospital
Southampton Research and Development Department. In-
formed consent was obtained from all healthy volunteers
prior to the enrolment.
Methyl- D9 choline chloride
Choline is an essential nutrient and a major constituent
of the phospholipid fraction of pulmonary surfactant.
Deuteriated choline (methyl-D9 choline chloride) is a stable
isotope of choline, which can be used to trace phospholipid
synthetic pathways. Recruited volunteers were intraven-
ously infused with methyl-D9 choline chloride (3.6 mg/kg
body weight) for a period of 3 hours in accordance with a
previous protocol [6].
Induced sputum, tracheal wash and small volume BALF
Sputum was induced by nebulised 4.5% hypertonic saline
[7]. The induction was performed up to 20 minutes and
stopped after sufficient material was obtained (~2 mls).
There were no events of bronchospasm or significant
drop (>15%) in peak flow during or after the process.
Induced sputum was immediately mixed with 5 mls of
phosphate buffered saline (PBS) and transferred to ice.
Tracheal wash and small volume broncholaveolar lavage
samples were obtained by a fibre-optic bronchoscope per-
formed under local anaesthesia without pre-medication.
The bronchoscope was passed through mouth with the
application of topical lidocaine (maximum of 4 mls 2% w/v
above vocal cords and 8 mls 1% w/v below vocal cords.
Ten mls of warmed saline (37°C) was applied at the distal
end of a right lower lobe distal segmental bronchus and
was suctioned. A greater than 50% recovery was deemed
to be adequate and if there was < 50% recovery, then a fur-
ther 10 mls of warmed saline was applied. TW samples
were obtained by flushing the trachea with 10mls warmed
saline with subsequent suction. The subsequent BALF
sampling was performed from a left lower lobe distal seg-
mental bronchus next day. There was no significant de-
cline in the FEV1 noted after the bronchoscopy. IS, BALF
and TW samples were filtered through a 100 μm mesh cell
strainer (BD Falcon) and centrifuged at 400 × g ×10
Table 1 Subject characteristics
Characteristics
Age (Range) 26 (18–36)
M:F 6:4
FEV1 (L) 4.22 ± 0.91*
Weight (kg) 78 ± 12*
Choline dose infused (mgs) 275 ± 54*
BALF Volume recovery (%) 42 ±20*
TW Volume recovery (%) 31 ± 12*
M, Male; F, Female; FEV1, Forced expiratory volume in 1 second; BALF,
Bronchoalveolar lavage fluid; TW, Tracheal wash. *Data expressed as mean ± SD.
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natant was aspirated and stored at −80°C.
Phospholipid extraction
Internal standards of 1 nmol dimyristoyl-PC (PC14:0/
14:0), 0.1 nmol heptadecyl_LPC (LPC17:0), 0.2 nmol of
dimyristoyl-PG (PG14:0/14:0) were added to all samples.
Phospholipid fraction was extracted by modified Bligh
and Dyer method [8]. Briefly, 800 μl of sample and the
addition of chloroform: methanol: water (v/v 2:2:1) re-
sulted in biphasic layer. The lower phospholipid rich
layer was aspirated carefully and dried under nitrogen
gas at 37°C.
Mass spectrometry analysis
Phospholipids were analyzed using a Xevo triple quadru-
pole mass spectrometer with electrospray ionisation in-
terface (Walters, UK). Dried lipid extracts were dissolved
in methanol:butanol:water:25%NH4 (6:2:1.6:0.4 v/v) and
delivered by direct infusion at 8 μl/min. PC, LPC and
sphingomyelin (SPH) species were identified by precursor
scans of the phosphocholine head group fragment, quanti-
fying endogenous PC and LPC species from the fragment
of mass to charge ratio (m/z) +184 and deuteriated
PC and LPC species from the m/z +193 fragment.
Phosphatidylglycerol (PG) and phosphatidylinositol (PI)
species were quantified from the negative ionisation
spectrum. The ion peaks were quantified using MassLynx
software with an in-house Excel macro programmed in
Visual Basic.
Determination of SP-D
The SP-D content was determined by enzyme- linked
immunosorbent assay (ELISA). The plates (96-well Nunc
MaxiSorp, Fisher Scientific) were coated with capture
antibody rfhSP-D 1ug/100ul per well in carbonate binding
buffer (Sigma-Aldrich) and incubated at 4° overnight. Plates
were washed three times (PBS/T 0.05% (v/v) Tween 20)
and blocked for one hour (PBS/T with 2% BSA) at room
temperature. After further wash, samples and standards
were incubated for one hour at room temperature. After
washing again the plates were incubated with streptavidin
horseradish peroxidise 1:10,000 (Sigma-Aldrich) for one
hour at room temperature. The plates were developed with
TMB (Sigma-Aldrich), reaction was stopped with 0.5 M
H2S04 and plates were read at 450 nm.
Statistics
The data are expressed as mean ± standard deviation
(SD). A two tailed paired Student’s T-test or two way
analysis of variance was performed with Bonferoni cor-
rection for multiple comparisons (Graph Pad Prism ver-
sion 5.04) to compare groups. Correlation was assessed
using Pearson coefficient.Results
Ten healthy volunteers were recruited. All participants had
sputum induction. One subject, however, was unable to
tolerate bronchoscopy leaving BALF/TW analysis for the
remaining nine participants. The clinical data and summary
of the participant characteristics were listed in Table 1.
Total phospholipid, phosphatidylcholine and SP-D
concentrations
The mean total phospholipid concentration in BALF
was 64.4 (range 29.1-145.1) nmol/ml, TW 51.8 (range
13.5- 158.7) nmol/ml and IS 8.0 (Range 3.2-14.1) nmol/ml.
The total PC concentration in BALF was relatively high
(49.9 range 18.6-121.8 nmol/ml) followed by TW (37.2
range 8.5-134.7 nmol/ml) compared to IS (5.8 range
2.4-10.5 nmol/ml). The mean SP-D concentration was 30.3
(range 9.9-67.6) ug/ml for BALF, 24.4 (range 11.8-48.1)
ug/ml for TW and 17.5 (range 1.5-85.0) ug/ml for IS. The
ratio of total SP-D/PC was much higher for IS, suggesting
the possibility of additional secretion of SP-D from airway
Clara cells (Table 2).
Endogenous lipid compositions
Phospholipid classes
The fractional phospholipid composition was investigated
by measuring the relative proportions of total PC, PG, PI,
SPH and LPC, each determined as the sum of these indi-
vidual molecular species. Phosphatidylethanolamine (PE)
and phosphatidylserine (PS) were present at low concentra-
tions and would have required additional analytical scans to
assess molecular composition and consequently, these
components are not presented here. PC (75%) followed by
PG (13%) were the most abundant phospholipids. Although
IS had a fractional increase in LPC and SPH, the phospho-
lipid molecular composition was comparable among all
sample types without any statistical difference (Figure 1).
Molecular composition of phospholipid classes
ESI/MS enabled a comprehensive analysis of molecular
compositions of PC, LPC and SPH using positive and PG
and PI with negative conditions. In BALF, di-saturated
Table 2 Concentrations of total phospholipid, phosphatidylcholine and surfactant protein D
BALF TW IS
Total PL (nmol/ml) 64.4 ± 37.1 (29.1–145.1) 51.8 ± 44.6 (13.5–158.7) †8.0 ± 3.8 (3.2–14.1)
Total PC (nmol/ml) 49.9 ± 32.8 (18.6–121.8) 37.2 ± 39.1 (8.5–134.7) †5.8 ± 2.9 (2.4–10.5)
SP-D (μg/ml) 30.3 ± 16.6 (9.9–67.6) 24.4 ± 13.9 (11.8–48.1) *17.5 ± 25.3 (1.5–85.0)
SP-D:PC 0.61 0.66 3.0
BALF, Bronchoalveolar lavage fluid; TW, Tracheal wash; IS, Induced sputum; PL, Phospholipid; PC, Phosphatidylcholine; SP-D, Surfactant protein D. *P < 0.05, †P < 0.01
(paired Student’s t-test) when compared with BALF, data expressed as mean ± SD.
Table 3 Phosphatidylcholine and lysophosphatidylcholine
molecular species composition from three isolation
methods
Surfactant PC composition (%)
PC Species BALF TW IS
PC16:0/14:0 8.8 ±0.9 7.9 ± 1.3 †7.0 ±1.6
PC16:0a/16:0 2.6 ±0.4 2.5 ± 0.4 3.0 ±0.6
Dushianthan et al. BMC Pulmonary Medicine 2014, 14:10 Page 4 of 9
http://www.biomedcentral.com/1471-2466/14/10PC16:0/16:0 was the dominant PC accounting for more
than 50% of total PC. This was followed by PC16:0/18:1
(13%), PC16:0/16:1 (9%), PC16:0/14:0 (9%) and PC16:0/
18:2 (6%). These findings were consistent with previously
published data [9]. When BALF PC composition was
compared with other recovery methods, significantly
lower proportions of PC16:0/16:0 were noted in both
TW and IS. Additionally, IS also had significantly lower
proportions of PC16:0/14:0 and PC16:0/16:1 and higher
composition of PC16:0/18:1 and PC18:0/18:2 compared
to BALF (Table 3). These differences suggest the pos-
sibility of dilution of surfactant PC by phospholipids
derived from non-alveolar origin in induced sputum.
PG molecular species mainly comprised PG16:0/18:1
(35%), PG18:1/18:1 (20%), PG18:0/18:1 (19%) while PI was
dominated by PI18:0/18:1 (22%), PI16:0/18:1 (20%) and
PI18:1/18:1 (20%). This finding of unsaturated molecular
species enrichment among PG and PI species is consistent
with previously published data [9,10]. There were no
significant differences in PG and PI compositions be-
tween BALF and TW. However, small but significantFigure 1 Fractional composition of phospholipids from
bronchoalveolar lavage fluid BALF), tracheal wash (TW)
and induced sputum (IS). PC, phosphatidylcholine; PG,
phosphatidylglycerol; PI, phosphatidylinositol; SPH, sphingomyelin;
LPC, lyso-phosphatidylcholine. Data expressed as mean ± SD. There
was no significant difference in overall phospholipids composition
between recovery methods.differences were noted in PG16:0/18:1 (3.3% lower, P =
0.01), PG18:1/18:1 (3.1% lower, P = 0.02), and PI18:0/
20:4 (4.8% higher, P = 0.02) in IS compared to BALF.
SPH species contain the same phosphocholine head
group as PC and consequently can be readily detected
by precursor scans of m/z + 184 in ESI/MS. Major SPH
species of BALF surfactant composed of SPH16:0 (65%),
SPH24:1 (20%) and SPH24:0 (10%). Other minor species
(SPH16:1, SPH18:0, SPH18:1, SPH18:2 and SPH20:4) were
detected at much lower abundance (<3%). There were
no significant differences in SPH molecular compos-
ition between BALF and TW. However, significant com-
positional differences with relative decrease in SPH16:0PC16:0/16:1 9.0 ±1.5 8.1 ± 1.9 †7.0 ±1.3
PC16:0/16:0 53.3 ± 3.6 ‡48.7 ± 6.4 ‡45.8 ±7.6
PC16:0/18:2 5.7 ±1.1 6.9 ±1.8 †7.6 ±1.8
PC16:0/18:1 12.6 ±1.6 13.9 ±1.9 ‡15.3 ±2.4
PC16:0/20:4 1.4 ±0.4 1.8 ±0.8 1.9 ±0.7
PC18:1/18:2 1.6 ±0.5 2.3 ±1.0 2.9 ±0.9
PC18:0/18:2 2.7 ±1.0 4.0 ±2.0 ‡5.4 ±2.0
PC18:0/18:1 1.3 ±0.6 2.1 ±1.2 2.9 ±1.3
PC18:1/20:4 0.4 ±0.2 0.6 ±0.4 0.5 ±0.2
PC18:0/20:4 0.6 ±0.4 1.2 ±0.9 0.9 ±0.4
Surfactant LPC composition %
LPC Species BALF TW IS
LPC16:0 71.7 ±6.0 ‡65.7 ±9.2 ‡54.4 ±14.8
LPC18:2 6.4 ±1.4 8.0 ±2.3 †12.5 ±5.4
LPC18:1 13.3 ±2.5 15.1 ±2.8 ‡21.6 ±6.2
LPC18:0 6.0 ±2.0 8.0 ±3.3 8.3 ±3.7
LPC20:4 2.6 ±1.8 3.2 ±2.1 3.2 ±2.2
BALF, Bronchoalveolar lavage fluid; TW, Tracheal wash; IS, Induced sputum; PC,
Phosphatidylcholine; LPC, Lysophosphatidylcholine. †P < 0.01, ‡P < 0.001. Data
are expressed as % (mean ± SD) composition of total selected species at time
points sampled.
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higher, P = 0.04) was noted in IS compared to BALF.
Total PC and fractional PC methyl-D9 Incorporation
Methyl-D9-choline incorporation was measured at two
time points (24 and 48 hours) for BALF and TW and
five time points (8, 24, 48, 72 and 96 hours) for IS. In
BALF, the total methyl-D9-choline incorporation into
surfactant PC was 0.35 ± 0.17% at 24 hours and 0.52 ±
0.15% at 48 hours with a rate of incorporation of 0.011
± 0.002% per hour until 48 hours (Figure 2). There was
no difference in total PC methyl-D9-choline incorpor-
ation between BALF and TW. In addition, there was a
positive correlation between BALF and TW for both
time points (r2 = 0.8344, P < 0.0001) for each individuals
(Figure 2).
The methyl-D9-choline incorporation into total PC
for IS was 0.13 ± 0.03% at 8 hours, showed a linear in-
corporation until 48 hours (r2 = 0.9984, P = 0.02) at a
rate of 0.012 ± 0.0005% per hour and remained relatively
stable between 48–96 hours. The fractional incorporation
into IS PC16:0/16:0 (0.17 ± 0.08%) was significantly lower
(P < 0.05) at 24 h than that into either BALF (0.31 ±
0.17%) or TW (0.29 ± 0.15%) (Figure 2). However, frac-
tional incorporation into IS PC16:0/16:0 reached equilib-
rium with other sample types at 48 hours. Although there
was a positive correlation between BALF and IS for bothFigure 2 Fractional incorporation of methyl-D9-choline into total phos
lavage fluid and induced sputum. Comparison of methyl-D9 incorporatio
(C) and bronchoalveolar lavage and induced sputum (D). The incorporation d
pattern as BALF. Results are calculated as from the abundance of methyl-D9-PC
species (mean ± SD. Incorporation into PC16:0/16:0 but not into total PC was
(PC, phosphatidylcholine; BALF, bronchoalveolar lavage fluid; IS, induced spututime points (r2 = 0.3572, P = 0.03), this association was
much weaker than that for TW and BALF (Figure 2).
Molecular specificity of D9-labelled PC species
The fractional composition of newly synthesized PC varied
considerably between sample type and with time. The pro-
portion of newly synthesized PC present as PC16:0/16:0
was consistently lower than that of endogenous PC com-
position for all sample types at 24 hours (Figure 3). In con-
trast, at 48 hours only IS still exhibited a lower proportion
of newly synthesized compared with endogenous PC16:0/
16:0. Inspecting the molecular specificity of PC synthesis
in more detail for TW (Table 4), PC16:0/16:0 was the sin-
gle molecular species significantly different from BALF at
both 24 hours and 48 hours. The pattern of newly synthe-
sized PC in IS was very different from BALF, with a total
of six significantly different components at 24 hours and
still two at 48 hours (Table 4).
LPC – Composition and methyl-D9-choline incorporation
The LPC composition mainly consisted of LPC16:0
(72%), LPC 18:1 (13%) and LPC18:2 (6%) (Table 3).
Overall total LPC methyl-D9-choline incorporation was
nearly twice than total PC incorporation for both time
points (24 and 48 hours). Furthermore, LPC16:0 methyl-
D9-choline incorporation was twice as that of methyl-D9-la-
belled PC16:0/16:0 and correlated positively (r2 = 0.9318,phatidylcholine (A) and PC16:0/16:0 (B) from bronchoalveolar
n into total PC between bronchoalveolar lavage and tracheal wash
ata for tracheal wash is not shown here as it followed the exact same
species expressed as a percentage of endogenous PC +methyl-D9-PC
significantly lower in IS than BALF at 24 h (*P < 0.05) but not at 48 h.
m, r2-Pearson correlation coefficient).
Figure 3 Molecular specificity of methyl-D9-choline
incorporation into dipalmitoylphosphatidylcholine. PC16:0/16:0
synthesis (open bars), expressed as a percentage of newly-synthesized
total PC, was compared with that of endogenous PC16:0/16:0 (closed
bars) at both 24 and 48 h for broncholaveolar lavage (BALF), tracheal
wash (TW) and induced sputum (IS) (mean ± SD; ‡P < 0.001 calculated
by two way analysis of variance).
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LPC 16:0 methyl-D9-labelling was much lower (~50%)
compared to other LPC species.
Discussion
This study demonstrates for the first time the molecular
compositions of various bronchoalveolar compartments
in human model and the surfactant molecular PC kinetics
from all these compartments. The results showed thatTable 4 Fractional composition of methyl-D9-choline incorpor
Newly synthesized D9-choline labelled mole
24 hours
PC species (%) BALF TW
PC16:0/14:0 10.0 ±2.5 7.8 ±2.8 7.9
PC16:0a/16:0 2.6 ±0.6 2.4 ±0.6 4.0
PC16:0/16:1 10.0 ± 2.5 8.9 ±2.4 7.03
PC16:0/16:0 46.9 ±3.0 ‡39.4 ±8.5 ‡22.
PC16:0/18:2 6.9 ±1.8 8.32 ±2.7 †12.
PC16:0/18:1 14.5 ±1.7 17.5 ±2.8 *18.
PC16:0/20:4 1.5 ±0.6 2.2 ±0.9 4.5
PC18:1/18:2 1.9 ±0.7 3.1 ±1.5 *5.8
PC18:0/18:2 3.2 ±0.9 5.4 ±2.8 ‡9.1
PC18:0/18:1 1.3 ±0.6 2.5 ±1.2 *4.7
PC18:1/20:4 0.5 ±0.2 0.9 ±0.5 1.5
PC18:0/20:4 0.7 ±0.4 1.7 ±0.9 2.1
BALF, Bronchoalveolar lavage fluid; TW, Tracheal wash; IS, Induced sputum; PC, Phos
BALF calculated by two way analysis of variance, data presented as mean ± SD.surfactant extracted by TW closely resembled that of
BALF. As ATII cells are the only source of pulmonary sur-
factant phospholipids, the significant positive correlation
of methyl-D9-choline incorporation between BALF and
TW suggests the mucocillary transit time of surfactant up
along the airways had little significant impact on surfac-
tant PC kinetics. Our analysis suggests that, despite the
presence of already-secreted surfactant lining the small
and large airway epithelium, a surfactant pool accessible
from the upper airways by tracheal wash is in isotopic
equilibrium with the alveolar surfactant pool.
Induced sputum had variable phospholipid compos-
ition and kinetics compared to BALF, possibly due to
several reasons. Firstly, IS phospholipids may represent
pools of surfactant with different temporal origins, with
some material newly secreted from the alveolus combined
with previously secreted surfactant embedded within the
mucus layer. Secondly, sputum induction is a complex
process and the exact origin of the induced sputum is
not always known. Furthermore, the contamination from
saliva and other non- surfactant phospholipids may have
interfered with surfactant assessment. Although IS had
qualitatively similar composition to that of alveolar surfac-
tant [10], it may not be an ideal model to study alveolar
surfactant metabolism. Thirdly, the relatively high content
of sphingomyelin in induced sputum suggests proportion
of IS phospholipid may be of cellular not surfactant
origin. Such a cellular origin of IS phospholipid may be-
come more significant in disease states characterized by
increased airway inflammatory cell infiltration.
Surfactant PC is synthesized de-novo by the CDP-
choline pathway. However, about 50% of PC16:0/16:0 is
produced by acyl-remodelling mechanisms catalysed byation into newly synthesized PC at 24 and 48 hours
cular PC composition at 24 and 48 hours
48 hours
IS BALF TW IS
±3.2 8.8 ±1.0 7.5 ±1.0 7.3 ±1.9
±2.9 2.3 ±0.5 2.3 ±0.5 3.5 ±0.9
±2.0 9.3 ±1.7 8.1 ±2.1 7.6 ±2.0
5 ±7.9 50.6 ±3.8 ‡45.4 ±7.3 ‡40.4 ±5.8
6 ±2.3 6.1 ±1.4 8.0 ±2.4 8.3 ±0.9
2 ±4.5 13.9 ±1.9 14.9 ±1.8 15.9 ±2.2
±1.7 1.5 ±0.5 2.0 ±0.7 2.1 ±1.0
±1.9 2.0 ±0.6 2.7 ±0.9 3.5 ±1.4
±3.0 2.8 ±1.1 4.6 ±2.3 *6.0 ±1.9
±2.3 1.5 ±0.8 2.3 ±1.8 3.3 ±1.1
±1.1 0.4 ±0.2 0.7 ±0.4 0.9 ±0.4
±0.9 0.7 ±0.5 1.3 ±1.1 1.1 ±0.4
phatidylcholine. *P < 0.05, †P < 0.01, ‡P < 0.001 for TW and IS compared with
Figure 4 Comparison between methyl-D9 incorporation into
PC16:0/16:0 and LPC16:0 isolated by bronchoalveolar lavage.
(r2- Pearson correlation coefficient).
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sphatidylcholine acyltransferase activities [11]. It is widely
assumed that surfactant PC synthesis and acyl-remodelling
processes precede subsequent secretion [11]. However,
our finding challenges this established concept. If the
surfactant PC is secreted after acyl-remodelling and
maturation process, the secreted surfactant PC16:0/16:0
compositions should reflect the endogenous composition
at all time points. Our study shows that the proportion
of methyl-D9-labelled PC16:0/16:0 is equilibrated with
endogenous composition only at 48 hours. This implies
that a certain proportion of PC is secreted even before
the acyl-remodelling mechanisms are complete.
This is the first to study to demonstrate the feasibility
of assessing surfactant lyso-PC metabolism in-vivo in
human subjects. This study shows that LPC16:0 is the
principle lyso-PC in pulmonary surfactant, but that total
LPC methyl-D9 incorporation was twice as that of total
PC. The methyl-D9-incorporation of LPC16:0 is much
higher than that of PC16:0/16:0 at both 24 and 48 hours.
This finding challenges the paradigm of that the LPC is
a formed by hydrolysis of secreted surfactant PC. The
much higher fractional incorporation of LPC compared
to PC precludes LPC coming from hydrolysis of newly
synthesized PC and emphasizes the complexity of the
underlying mechanisms of surfactant synthesis and secre-
tion. These observations strongly support the possibility,
at least in healthy individuals, that LPC is secreted to-
gether with the other surfactant phospholipid rather than
simply being a consequence of hydrolysed PC. While
phospholipase-mediated hydrolysis of secreted surfactantphospholipid remains a possibility in inflammatory lung
disease, a further implication of our results, supported
by the strong correlation of stable isotope label incorpo-
rations into LPC16:0 and PC16:0/16:0 (Figure 4) is that
secreted LPC may be ultimately a consequence of acyl
remodelling mechanisms within ATII cells.
Investigators have also used other stable isotopes such
as 13C-glucose, 13C-fatty acids or deuteriated water to
assess fractional synthetic rates (FSR) of saturated PC
(SatPC) to characterise surfactant kinetics in neonates
[12-14] and adults [15]. SatPC is the major PC surfactant
component and a clinical marker of lung injury and sur-
factant derangement [16]. Measuring SatPC from deu-
teriated water enables maintenance of a steady state
condition more easily, and therefore results can be com-
pared between groups of patients with different clinical
conditions. These novel studies provided significant
insights into surfactant metabolism in humans but have
some limitations. First, these methodologies initially used
osmium tetroxide oxidation of unsaturated phospholipid
to generate a SatPC fraction. Consequently, minimal infor-
mation can be obtained about the molecular specificity of
surfactant PC metabolism [17]. Second, the laborious sam-
ple preparation required for these studies has precluded
the early diagnostic application of these methodologies
to individuals with lung diseases. In contrast, the use of
ESI-MS to monitor stable isotope incorporations requires
minimal sample preparation and has the potential to gen-
erate diagnostic surfactant kinetic results in a time scale
consistent with making clinical treatment decisions for
individual patients with acute respiratory compromise.
In our study, tracheal secretions were accessed by the
use of a bronchoscope. It is entirely plausible that a
small amount of the BALF from distal alveolus may have
contaminated the tracheal washings as both of these
procedures were conducted in a single setting. If the com-
positional similarities were due to this contamination, one
might have seen significant dilution effect in the mag-
nitude of 1:10 reduction in the fractional phospholipid
concentrations from tracheal wash. However, this was not
the case and this absence of dilution effect indicate any
contamination of tracheal wash from alveolar material is
minimal.
Another limitation of this study was the measurements
of absolute amounts of phospholipid subclasses and PC
species may have been influenced by the variability in
the sample recovery. Nevertheless it was reassuring to
see overall compositional similarities from all endo-
bronchial sampling. Furthermore, kinetic data regarding
methyl-D9 incorporation patterns are unlikely to be in-
fluenced by this variability in recovery as the incorpor-
ation data was corrected for the endogenous material.
Acute lung injury and ARDS are characterized by signifi-
cant quantitative and qualitative alterations in surfactant
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therapeutic attempts with exogenous surfactant remain
unhelpful in this population [18]. The complexity of
ARDS pathogenesis suggests several possible mechanisms
for surfactant dysfunction, such as impaired synthesis and
secretion, increased hydrolysis, proteolysis and oxidation
or functional inhibition by infiltrating plasma proteins.
However, in-vivo human models investigating such com-
plex underlying mechanisms are lacking. Deficient under-
standing of the potential multiple mechanisms of aberrant
surfactant metabolism in this disease cohort may in part
explain the lack of anticipated clinical benefits from ex-
ogenous surfactant replacement strategies. Application
of stable isotope studies in this population may possibly
identify underlying phenotypes to characterise patients
according to pathological mechanisms of surfactant
dysfunction. Tracheal washings substituted for quan-
titative bronchoalveolar lavage may be an alterative for
surfactant isolation in patients otherwise unable to tol-
erate invasive procedures without clinical compromise.
Conclusions
This study comprehensibly demonstrates the feasibility
of performing stable isotope labelling to study surfactant
phospholipid kinetics from bronchoalveolar compart-
ments in healthy adults. Tracheal secretions were more
closely resembled alveolar surfactant composition com-
pared to induced sputum. Although several differences
were noted in induced sputum phospholipid compos-
ition and turnover compared to BALF, the overall rela-
tive changes were small. This study illustrates the utility
of various recovery methods to study in-vivo surfactant
metabolism in humans which can be applied in disease
states such as ARDS to possibly identify variation in sur-
factant metabolism among patients.
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